Significant response to atezolizumab plus bevacizumab treatment in unresectable hepatocellular carcinoma with major portal vein tumor thrombus: a case report

Figures

• 

  Fig. 1. Abdominal computed tomography revealing a huge hepatocellular carcinoma located at segment 4 (white arrow). The portal vein tumor thrombus has spread from the adjacent portal vein to the left portal trunk, main portal trunk, through to the contralateral right portal trunk (arrowhead). The tip of the portal vein tumor thrombus has invaded into the bifurcation of the anterior and posterior branches; the anterior branch is filled with tumor thrombus, while the posterior branch is filled with tumors or blood thrombi

• 

  Fig. 2. Abdominal computed tomography showing size reduction of the main tumor and the portal vein tumor thrombus (white arrow). The tip of the portal vein tumor thrombus has regressed from the bifurcation of the anterior and posterior branches to the left trunk, and the right portal vein is recanalized. Serum alfa-fetoprotein level decreased from 90,700 ng/mL before the treatment to 18,371 ng/mL (3 weeks later) and 89 ng/mL (2 months later). AFP, alfa-fetoprotein

• 

  Fig. 3. Transition of the serum alfa-fetoprotein level during the treatment course. AFP, alfa-fetoprotein; Ate/bev, atezolizumab plus bevacizumab treatment; Ate, atezolizumab treatment